38.53
price up icon15.26%   5.10
pre-market  Pre-market:  37.01   -1.52   -3.94%
loading
Monopar Therapeutics Inc stock is traded at $38.53, with a volume of 71,257. It is up +15.26% in the last 24 hours and up +9.74% over the past month.
See More
Previous Close:
$33.43
Open:
$31.7
24h Volume:
71,257
Relative Volume:
1.38
Market Cap:
$204.01M
Revenue:
-
Net Income/Loss:
$-7.12M
P/E Ratio:
-16.75
EPS:
-2.3
Net Cash Flow:
$-6.82M
1W Performance:
+1.13%
1M Performance:
+9.74%
6M Performance:
+694.43%
1Y Performance:
+5,920%
1-Day Range:
Value
$31.70
$42.00
1-Week Range:
Value
$31.70
$43.00
52-Week Range:
Value
$0.3438
$54.30

Monopar Therapeutics Inc Stock (MNPR) Company Profile

Name
Name
Monopar Therapeutics Inc
Name
Phone
(847) 388-0349
Name
Address
1000 SKOKIE BLVD SUITE 350, WILMETTE
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
MNPR's Discussions on Twitter

Compare MNPR with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
MNPR
Monopar Therapeutics Inc
38.53 204.01M 0 -7.12M -6.82M -2.30
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
483.49 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
625.60 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
583.62 35.60B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
266.83 34.53B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
274.78 29.15B 3.81B -644.79M -669.77M -6.24

Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-19-25 Resumed Piper Sandler Overweight
Jan-10-25 Initiated Piper Sandler Overweight
Oct-11-24 Initiated Rodman & Renshaw Buy
Jan-28-21 Initiated ROTH Capital Buy

Monopar Therapeutics Inc Stock (MNPR) Latest News

pulisher
01:49 AM

What is HC Wainwright’s Forecast for MNPR FY2029 Earnings? - Defense World

01:49 AM
pulisher
Apr 02, 2025

Monopar Therapeutics downgraded to Hold from Buy at JonesResearch - TipRanks

Apr 02, 2025
pulisher
Apr 02, 2025

We Think Monopar Therapeutics (NASDAQ:MNPR) Can Easily Afford To Drive Business Growth - Yahoo Finance

Apr 02, 2025
pulisher
Apr 02, 2025

Monopar Therapeutics (NASDAQ:MNPR) Receives “Buy” Rating from HC Wainwright - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

Monopar Therapeutics Stock Hits 52-Week High at $38.91 - MSN

Apr 01, 2025
pulisher
Apr 01, 2025

Monopar Therapeutics Inc: Strategic Advancements and Promising Financial Projections Justify Buy Rating - TipRanks

Apr 01, 2025
pulisher
Mar 31, 2025

Monopar Therapeutics reports Q4 EPS ($2.23) vs. (60c) last year - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Monopar Therapeutics sees cash runway through December 31, 2026 - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Monopar Therapeutics SEC 10-K Report - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Monopar Secures 2-Year Runway with $60M War Chest, Advances Wilson Disease Drug - Stock Titan

Mar 31, 2025
pulisher
Mar 27, 2025

MNPR Stock Price and Chart — NASDAQ:MNPR - TradingView

Mar 27, 2025
pulisher
Mar 21, 2025

Here's Why Momentum in Monopar Therapeutics (MNPR) Should Keep going - Yahoo Finance

Mar 21, 2025
pulisher
Mar 21, 2025

Piper Sandler Reaffirms “Overweight” Rating for Monopar Therapeutics (NASDAQ:MNPR) - Defense World

Mar 21, 2025
pulisher
Mar 20, 2025

Monopar Therapeutics (MNPR) to Release Quarterly Earnings on Thursday - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Monopar a new overweight at Piper Sandler on rare disease asset - Seeking Alpha

Mar 19, 2025
pulisher
Mar 19, 2025

Piper Sandler sets Monopar stock at $76 with Overweight rating - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Buy Rating for Monopar Therapeutics Inc. Driven by Strategic Acquisition and ALXN1840 Potential - TipRanks

Mar 19, 2025
pulisher
Mar 19, 2025

Piper Sandler sets Monopar stock at $76 with Overweight rating By Investing.com - Investing.com UK

Mar 19, 2025
pulisher
Mar 16, 2025

(MNPR) Trading Report - news.stocktradersdaily.com

Mar 16, 2025
pulisher
Mar 08, 2025

Monopar Therapeutics Inc.'s (NASDAQ:MNPR) 19% loss last week hit both individual investors who own 33% as well as institutions - Simply Wall St

Mar 08, 2025
pulisher
Mar 04, 2025

Monopar Therapeutics: Strong Data, But There Are Risks (NASDAQ:MNPR) - Seeking Alpha

Mar 04, 2025
pulisher
Mar 03, 2025

Monopar Therapeutics appoints new CFO - Investing.com

Mar 03, 2025
pulisher
Mar 03, 2025

Monopar Therapeutics Appoints Quan Vu as New CFO - TipRanks

Mar 03, 2025
pulisher
Mar 03, 2025

Monopar Therapeutics Inc Says On Feb 28, CFO Karthik Radhakrishnan'S Employment Terminated - Marketscreener.com

Mar 03, 2025
pulisher
Mar 03, 2025

Monopar Therapeutics appoints new CFO By Investing.com - Investing.com Australia

Mar 03, 2025
pulisher
Feb 24, 2025

Monopar Therapeutics appoints new board member - Investing.com

Feb 24, 2025
pulisher
Feb 24, 2025

Monopar Therapeutics appoints new board member By Investing.com - Investing.com UK

Feb 24, 2025
pulisher
Feb 24, 2025

Monopar Therapeutics Appoints Lavina Talukdar to Board - TipRanks

Feb 24, 2025
pulisher
Feb 23, 2025

Trend Tracker for (MNPR) - Stock Traders Daily

Feb 23, 2025
pulisher
Feb 19, 2025

Copper wired: Monopar to electrify Wilson disease? - BioWorld Online

Feb 19, 2025
pulisher
Feb 13, 2025

Q1 EPS Estimate for Monopar Therapeutics Raised by Analyst - MarketBeat

Feb 13, 2025
pulisher
Feb 12, 2025

Learn to Evaluate (MNPR) using the Charts - Stock Traders Daily

Feb 12, 2025
pulisher
Feb 11, 2025

Brookline Capital Management Forecasts MNPR Q1 Earnings - Defense World

Feb 11, 2025
pulisher
Feb 06, 2025

Monopar's Incredible Journey From $5 To $50 In Less Than 5 Months - RTTNews

Feb 06, 2025
pulisher
Feb 04, 2025

Why Monopar Therapeutics Inc (MNPR) Is Skyrocketing So Far In 2025 - MSN

Feb 04, 2025
pulisher
Feb 03, 2025

Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025 - Insider Monkey

Feb 03, 2025
pulisher
Jan 27, 2025

What's Going On With Cancer-Focused Monopar Therapeutics Stock Today? - MSN

Jan 27, 2025
pulisher
Jan 26, 2025

What is HC Wainwright’s Forecast for MNPR FY2026 Earnings? - Defense World

Jan 26, 2025
pulisher
Jan 24, 2025

Analysts Set Expectations for MNPR FY2029 Earnings - MarketBeat

Jan 24, 2025
pulisher
Jan 24, 2025

What is HC Wainwright's Forecast for MNPR FY2026 Earnings? - MarketBeat

Jan 24, 2025
pulisher
Jan 24, 2025

Monopar Therapeutics Stock Hits 52-Week High at $38.91 By Investing.com - Investing.com South Africa

Jan 24, 2025
pulisher
Jan 23, 2025

Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics - PR Newswire

Jan 23, 2025
pulisher
Jan 23, 2025

Monopar Therapeutics price target raised to $40 from $22 at H.C. Wainwright - Yahoo Finance

Jan 23, 2025
pulisher
Jan 23, 2025

Monopar Therapeutics Joins Elite Helix 51 Biomedical Hub to Accelerate Cancer Treatment Research - Stock Titan

Jan 23, 2025
pulisher
Jan 22, 2025

Monopar Therapeutics (NASDAQ:MNPR) Price Target Raised to $40.00 - MarketBeat

Jan 22, 2025
pulisher
Jan 21, 2025

All You Need to Know About Monopar Therapeutics (MNPR) Rating Upgrade to Buy - MSN

Jan 21, 2025
pulisher
Jan 21, 2025

Up 1,000% in 2024, Wall Street Believes This Growth Stock Can Still Skyrocket - MSN

Jan 21, 2025

Monopar Therapeutics Inc Stock (MNPR) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$73.44
price up icon 2.00%
$68.32
price up icon 0.56%
$31.28
price up icon 0.35%
$20.46
price up icon 8.83%
$93.32
price up icon 3.36%
biotechnology ONC
$274.78
price up icon 1.38%
Cap:     |  Volume (24h):